JP2014520072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520072A5 JP2014520072A5 JP2014508130A JP2014508130A JP2014520072A5 JP 2014520072 A5 JP2014520072 A5 JP 2014520072A5 JP 2014508130 A JP2014508130 A JP 2014508130A JP 2014508130 A JP2014508130 A JP 2014508130A JP 2014520072 A5 JP2014520072 A5 JP 2014520072A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- group
- alkenyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 26
- -1 cyano, amino, phenyl Chemical group 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 13
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims description 12
- 206010003805 Autism Diseases 0.000 claims description 7
- 208000020706 Autistic disease Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000003956 synaptic plasticity Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 claims description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 2
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims description 2
- 101001000686 Homo sapiens 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 claims description 2
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims description 2
- 101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 claims description 2
- 101000745175 Homo sapiens Neuronal acetylcholine receptor subunit alpha-5 Proteins 0.000 claims description 2
- 101001099423 Homo sapiens Proenkephalin-A Proteins 0.000 claims description 2
- 102100039909 Neuronal acetylcholine receptor subunit alpha-4 Human genes 0.000 claims description 2
- 102100039907 Neuronal acetylcholine receptor subunit alpha-5 Human genes 0.000 claims description 2
- 102100038931 Proenkephalin-A Human genes 0.000 claims description 2
- 102100024622 Proenkephalin-B Human genes 0.000 claims description 2
- 101100162976 Sus scrofa APOR gene Proteins 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 2
- 108010074732 preproenkephalin Proteins 0.000 claims description 2
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical group C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 105
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 60
- 125000003342 alkenyl group Chemical group 0.000 claims 40
- 229910052739 hydrogen Inorganic materials 0.000 claims 40
- 239000001257 hydrogen Substances 0.000 claims 40
- 125000001424 substituent group Chemical group 0.000 claims 40
- 150000002431 hydrogen Chemical class 0.000 claims 30
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 25
- 150000002367 halogens Chemical class 0.000 claims 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 10
- 150000001408 amides Chemical class 0.000 claims 10
- 150000001412 amines Chemical class 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 5
- 150000001204 N-oxides Chemical class 0.000 claims 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000036280 sedation Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479593P | 2011-04-27 | 2011-04-27 | |
| US61/479,593 | 2011-04-27 | ||
| US201161527744P | 2011-08-26 | 2011-08-26 | |
| US61/527,744 | 2011-08-26 | ||
| PCT/US2012/035547 WO2012149389A2 (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520072A JP2014520072A (ja) | 2014-08-21 |
| JP2014520072A5 true JP2014520072A5 (cg-RX-API-DMAC7.html) | 2016-09-23 |
| JP6035326B2 JP6035326B2 (ja) | 2016-11-30 |
Family
ID=47073094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508130A Expired - Fee Related JP6035326B2 (ja) | 2011-04-27 | 2012-04-27 | アルツハイマー病、ハンチントン病、自閉症及びその他の疾患を治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140107037A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3679931A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6035326B2 (cg-RX-API-DMAC7.html) |
| KR (5) | KR20180095096A (cg-RX-API-DMAC7.html) |
| CN (2) | CN108283712A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012249397B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013027554A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2834286A1 (cg-RX-API-DMAC7.html) |
| EA (2) | EA201790653A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1258231A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX357761B (cg-RX-API-DMAC7.html) |
| SG (2) | SG194230A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012149389A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033757A1 (en) | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| BR112012020142A2 (pt) | 2010-02-11 | 2020-08-18 | Northwestern University | moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos. |
| CN105026401A (zh) | 2013-01-29 | 2015-11-04 | 诺雷克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| ES2935352T3 (es) | 2013-01-29 | 2023-03-06 | Aptinyx Inc | Moduladores de receptores NMDA de espiro-lactama y sus usos |
| MX375286B (es) | 2013-01-29 | 2025-03-06 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| BR112015018094A2 (pt) | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor nmda de espiro-lactama e usos dos mesmos |
| JP6419087B2 (ja) | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| JP6603668B2 (ja) * | 2013-10-28 | 2019-11-06 | ノーレックス インコーポレイテッド | Ｎｍｄａ受容体モジュレーター及びプロドラッグ、塩、並びにこれらの使用 |
| CN111920412A (zh) * | 2013-12-13 | 2020-11-13 | 西北大学 | 治疗脑部病症或鉴定与其相关的生物标记的方法 |
| CN105327349A (zh) * | 2014-06-18 | 2016-02-17 | 上海翰森生物医药科技有限公司 | Nmda受体拮抗剂的医药用途及其药物组合物 |
| JP6688748B2 (ja) * | 2014-06-23 | 2020-04-28 | ノースウェスタン ユニバーシティ | 片頭痛の治療または改善方法 |
| KR20180102052A (ko) * | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102128675B1 (ko) | 2016-05-19 | 2020-06-30 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| JP2019527235A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| KR102503590B1 (ko) | 2016-08-01 | 2023-02-24 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| SG11201900551WA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| CA3031563C (en) | 2016-08-01 | 2023-12-05 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| EA201990424A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
| SG11202007256PA (en) | 2018-01-31 | 2020-08-28 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| KR102415692B1 (ko) | 2020-09-01 | 2022-07-05 | 건국대학교 글로컬산학협력단 | 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| GB0018272D0 (en) * | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| JP2005518411A (ja) * | 2002-01-16 | 2005-06-23 | エンド ファーマシューティカルズ インコーポレーテッド | 中枢神経系の障害を治療する製薬組成物及び方法 |
| US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| RS52471B (sr) * | 2005-03-24 | 2013-02-28 | Emory University | Režimi doziranja za lečenje traumatske povrede mozga progesteronom |
| US9783851B2 (en) * | 2008-02-20 | 2017-10-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| WO2010033757A1 (en) * | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
| PL2485751T3 (pl) * | 2009-10-05 | 2014-10-31 | Univ Northwestern | GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie |
-
2012
- 2012-04-27 EP EP20151676.2A patent/EP3679931A3/en not_active Withdrawn
- 2012-04-27 JP JP2014508130A patent/JP6035326B2/ja not_active Expired - Fee Related
- 2012-04-27 EP EP12777016.2A patent/EP2701721A4/en not_active Ceased
- 2012-04-27 SG SG2013079603A patent/SG194230A1/en unknown
- 2012-04-27 KR KR1020187022910A patent/KR20180095096A/ko not_active Ceased
- 2012-04-27 EA EA201790653A patent/EA201790653A1/ru unknown
- 2012-04-27 KR KR1020197008907A patent/KR20190037359A/ko not_active Ceased
- 2012-04-27 EA EA201391581A patent/EA029999B1/ru unknown
- 2012-04-27 CA CA2834286A patent/CA2834286A1/en not_active Abandoned
- 2012-04-27 CN CN201711451914.XA patent/CN108283712A/zh active Pending
- 2012-04-27 MX MX2013012526A patent/MX357761B/es active IP Right Grant
- 2012-04-27 KR KR1020207011211A patent/KR20200043534A/ko not_active Ceased
- 2012-04-27 KR KR1020217011613A patent/KR20210046843A/ko not_active Ceased
- 2012-04-27 US US14/114,376 patent/US20140107037A1/en not_active Abandoned
- 2012-04-27 KR KR1020137031028A patent/KR20140043078A/ko not_active Ceased
- 2012-04-27 SG SG10202010665YA patent/SG10202010665YA/en unknown
- 2012-04-27 BR BR112013027554A patent/BR112013027554A2/pt not_active Application Discontinuation
- 2012-04-27 AU AU2012249397A patent/AU2012249397B2/en not_active Ceased
- 2012-04-27 CN CN201280027349.3A patent/CN103974712A/zh active Pending
- 2012-04-27 WO PCT/US2012/035547 patent/WO2012149389A2/en not_active Ceased
-
2016
- 2016-04-14 US US15/098,985 patent/US20170049845A1/en not_active Abandoned
-
2018
- 2018-10-23 US US16/168,242 patent/US20190209642A1/en not_active Abandoned
-
2019
- 2019-01-14 HK HK19100591.2A patent/HK1258231A1/zh unknown
-
2020
- 2020-05-05 US US16/867,324 patent/US20210169964A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520072A5 (cg-RX-API-DMAC7.html) | ||
| CA2834286A1 (en) | Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders | |
| US10501458B2 (en) | Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors | |
| JP2012503008A5 (cg-RX-API-DMAC7.html) | ||
| RU2010122261A (ru) | Производные амина и их применение для лечения офтальмологических заболеваний и расстройств | |
| JP2013135695A5 (cg-RX-API-DMAC7.html) | ||
| TW201542553A (zh) | 氮雜吡啶酮化合物及其用途 | |
| JP2019514884A (ja) | Ｅｚｈ２インヒビターおよびそれらの使用 | |
| JP2018515492A5 (cg-RX-API-DMAC7.html) | ||
| CN111788191A (zh) | 用于治疗癌症的1-(哌啶基羰基甲基)-2-氧代哌嗪衍生物 | |
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| EA201490569A1 (ru) | Полиморфная форма гидрохлорида придопидина | |
| CN107353317A (zh) | 具有修饰的亚基间键和/或端基的寡核苷酸类似物 | |
| JP2008513516A5 (cg-RX-API-DMAC7.html) | ||
| SI3018132T1 (en) | Condensed imidazole derivatives useful as IDO inhibitors | |
| AU2021200164A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| JP2016516074A5 (cg-RX-API-DMAC7.html) | ||
| WO2020069339A1 (en) | Mutant reverse tetracycline transactivators for expression of genes | |
| JP2012513416A5 (cg-RX-API-DMAC7.html) | ||
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| MY193754A (en) | Treatment for parkinson's disease | |
| JP2013542267A5 (cg-RX-API-DMAC7.html) | ||
| JP2013525356A5 (cg-RX-API-DMAC7.html) | ||
| CA2818025A1 (en) | Pyridazine derivatives, compositions and methods for treating cognitive impairment | |
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 |